{"name":"Jomaa Pharma GmbH","slug":"jomaa-pharma-gmbh","ticker":"","exchange":"","domain":"","description":"Jomaa Pharma GmbH is a specialty pharmaceutical company focused on the development of novel antimalarial treatments. The company is advancing two drug candidates in Phase 2 clinical trials, both of which aim to address the growing challenge of drug-resistant malaria.","hq":"","founded":0,"employees":"N/A","ceo":"","sector":"","stockPrice":0,"stockChange":0,"stockChangePercent":0,"marketCap":"","metrics":{"revenue":0,"revenueGrowth":0,"grossMargin":0,"rdSpend":0,"netIncome":0,"cash":0,"dividendYield":0,"peRatio":0,"fiscalYear":"FY2026"},"revenueBreakdown":[],"timeline":[{"date":"2026-07-28","label":"Q2 2026 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2026-10-28","label":"Q3 2026 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-01-28","label":"Q4 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-04-28","label":"Q1 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-07-28","label":"Q2 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-10-28","label":"Q3 2027 Earnings","type":"earnings","sentiment":"neutral"}],"diseaseAreas":[{"name":"Infectious Disease","slug":"infectious-disease","revenue":0,"percentOfTotal":0,"drugCount":1,"colorKey":"oncology","drugs":[{"name":"Fosmidomycin and Clindamycin co-administration","genericName":"Fosmidomycin and Clindamycin co-administration","slug":"fosmidomycin-and-clindamycin-co-administration","indication":"Treatment of malaria caused by Plasmodium falciparum","status":"phase_2"}]}],"pipeline":[{"name":"Fosmidomycin and Clindamycin co-administration","genericName":"Fosmidomycin and Clindamycin co-administration","slug":"fosmidomycin-and-clindamycin-co-administration","phase":"phase_2","mechanism":"Fosmidomycin inhibits the enzyme 1-deoxy-D-xylulose-5-phosphate reductoisomerase (DXR), which is involved in the biosynthesis of isoprenoids, while clindamycin inhibits protein synthesis by binding to the 50S ribosomal subunit.","indications":["Treatment of malaria caused by Plasmodium falciparum","Treatment of bacterial infections, including those caused by Streptococcus and Staphylococcus species"],"catalyst":""}],"recentEvents":[],"realNews":[],"patents":[],"drugCount":1,"phaseCounts":{"phase_2":1},"enrichmentLevel":2,"visitCount":2,"keyCompetitors":[],"therapeuticFocus":[],"financials":null,"yahoo":null}